By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > ARB > Valsartan

Valsartan

GMJ
Last updated: 01/06/2026 20:19
By
GMJ News Desk
Share
6 Min Read
SHARE
4 min read|725 words

What is Valsartan?

Valsartan is a prescription medication that belongs to a class of drugs called angiotensin receptor blockers (ARBs). It is primarily used to treat high blood pressure (hypertension) and heart failure by helping blood vessels relax and widen. This medication is also prescribed to improve survival after heart attacks and to protect kidney function in people with diabetes.

Uses

  • High blood pressure (hypertension): Valsartan helps lower blood pressure by blocking certain hormones that cause blood vessels to constrict, reducing the risk of stroke, heart attack, and kidney problems.
  • Heart failure: Used to improve heart function and reduce symptoms like shortness of breath and swelling in patients whose hearts cannot pump blood effectively.
  • Post-heart attack treatment: Prescribed to improve survival rates and reduce the risk of further cardiovascular events in patients who have recently experienced a heart attack.
  • Diabetic kidney protection: Helps protect kidney function in people with type 2 diabetes who show signs of kidney damage, slowing the progression of diabetic nephropathy.
  • Cardiovascular risk reduction: May be used as part of a comprehensive treatment plan to reduce overall cardiovascular risk in high-risk patients.

How it works

Valsartan works by blocking angiotensin II receptors in blood vessels and other tissues throughout the body. Angiotensin II is a hormone that causes blood vessels to narrow and promotes sodium and water retention, which increases blood pressure. By preventing angiotensin II from binding to its receptors, valsartan allows blood vessels to remain relaxed and dilated, effectively lowering blood pressure and reducing the workload on the heart.

Side effects

Common side effects:

  • Dizziness or lightheadedness
  • Fatigue or weakness
  • Headache
  • Diarrhea
  • Back pain
  • Cough (less common than with ACE inhibitors)
  • Upper respiratory tract infections
  • Nausea

Serious side effects to watch for:

Submit Your Paper
GMJ_Submit_Banner
  • Severe drop in blood pressure (hypotension)
  • Kidney problems or worsening kidney function
  • High potassium levels (hyperkalemia)
  • Allergic reactions including swelling of face, lips, tongue, or throat
  • Severe dehydration

Warnings and precautions

  • Pregnancy: Valsartan should not be used during pregnancy as it can cause serious harm or death to the developing fetus. Women of childbearing age should use effective contraception while taking this medication.
  • Kidney function: Patients with kidney disease or those taking other medications that affect kidney function require regular monitoring, as valsartan can worsen kidney problems in some individuals.
  • Liver impairment: Patients with severe liver disease should use valsartan with caution, and dosage adjustments may be necessary.
  • Dehydration risk: Patients who are dehydrated, have low sodium levels, or are taking diuretics may be at increased risk of experiencing dangerously low blood pressure when starting valsartan.
  • Surgery considerations: Patients should inform their healthcare providers about valsartan use before any surgical procedures, as the medication may interact with anesthesia.

Interactions

  • ACE inhibitors: Combining with ACE inhibitors increases the risk of kidney problems and dangerously low blood pressure.
  • Potassium supplements and salt substitutes: Can lead to dangerously high potassium levels in the blood.
  • Diuretics: May enhance blood pressure-lowering effects and increase risk of dehydration and electrolyte imbalances.
  • NSAIDs (ibuprofen, naproxen): Can reduce the effectiveness of valsartan and increase the risk of kidney damage.
  • Lithium: Valsartan may increase lithium levels in the blood, potentially leading to lithium toxicity.
  • Rifampin: May reduce the effectiveness of valsartan by increasing its breakdown in the body.
  • Aliskiren: Should not be used together in patients with diabetes or kidney problems due to increased risk of serious side effects.
  • Warfarin: May require more frequent monitoring of blood clotting times when used together.

Check interactions with the GMJ Interaction Checker

Dosage

For hypertension, the typical starting dose is 80-160 mg once daily, which may be increased to a maximum of 320 mg daily based on blood pressure response. For heart failure, treatment usually begins with 40 mg twice daily, potentially increasing to 80-160 mg twice daily as tolerated. Post-heart attack treatment typically starts at 20 mg twice daily, gradually increasing to a target dose of 160 mg twice daily. Dosages for kidney protection in diabetic patients usually range from 80-320 mg once daily. All dosage adjustments should be made gradually under medical supervision, and individual dosing must always be determined by a healthcare provider based on the patient’s specific condition, response to treatment, and other health factors.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Valsartan." GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/drug/valsartan/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Endometriosis Affects 10% of Women Yet Faces Chronic Under-recognition, BBC Investigation Reveals

BBC investigation reveals endometriosis affects 10% of women yet faces chronic under-recognition,…

Medical School Diversity Gains Not Translating to Diverse Physician Workforce

Despite medical schools successfully diversifying enrollment, these gains aren't translating to physician…

Maternity Staff Used Offensive Terms for Patients, BBC Investigation Reveals

BBC Panorama investigation reveals maternity staff at Nottingham University Hospitals NHS Trust…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Losartan

By
GMJ News Desk
01/06/2026

Losartan

By
GMJ News Desk
01/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up